STOCK TITAN

Omnicell, Inc. - OMCL STOCK NEWS

Welcome to our dedicated news page for Omnicell (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Omnicell's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Omnicell's position in the market.

News
Rhea-AI Summary
Omnicell, Inc. announces XT Amplify, a multi-year innovation program aimed at maximizing value and outcomes for hospitals and healthcare facilities using the XT Automated Dispensing System. The program includes solutions to enhance efficiency, reduce errors, and optimize the use of Omnicell's technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Omnicell, Inc. (OMCL) will release its Q1 2024 financial results on May 2, 2024, followed by a conference call. Interested parties can dial in or access the webcast. The Company is a leader in pharmacy care delivery transformation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
-
Rhea-AI Summary
Omnicell, Inc. (OMCL) to present at KeyBanc Annual Life Sciences & MedTech Investor Forum. Webcasts available on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences
Rhea-AI Summary
Omnicell, Inc. (OMCL) reported full-year 2023 GAAP revenues of $1.147 billion, with a net loss of $20 million. However, the company achieved a Non-GAAP EBITDA of $138 million and Non-GAAP net income per diluted share of $1.91. Net Cash Provided by Operating Activities stood at $181 million, with Non-GAAP Free Cash Flow of $126 million. The company's chairman, president, CEO, and founder, Randall Lipps, expressed satisfaction with the financial results, stating that they were generally in line with expectations for the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.35%
Tags
-
Rhea-AI Summary
Omnicell, Inc. (OMCL) is set to release its financial results for the fourth quarter and full year 2023 on February 8, 2024. The company will host a conference call and webcast to discuss the results. Interested parties can listen to the live call and presentation or access the archived webcast through the Investor Relations section of Omnicell’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
-
Rhea-AI Summary
Omnicell, Inc. (OMCL) will present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 at 1:00 p.m. ET. The company is a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies. Live and archived webcasts of the presentation will be available through the Omnicell website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
conferences
Rhea-AI Summary
Omnicell, Inc. has been selected by Kentucky-based Baptist Health to implement its Central Pharmacy Dispensing Service. The service aims to address labor challenges, improve clinical and financial outcomes, and enhance safety and dispensing accuracy. By leveraging advanced robotics, dispensing optimization tools, and remote and onsite experts, the solution automates and optimizes pharmacy labor and workflows, reducing pharmacists' dispensing tasks by 75% on average.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.26%
Tags
none
-
Rhea-AI Summary
Omnicell, Inc. announces Q3 2023 results with total GAAP revenues of $299 million, down 14% YoY. GAAP net income per diluted share was $0.12, while non-GAAP net income per diluted share was $0.62. The company plans to take cost containment actions, including a headcount reduction, with expected non-recurring charges of $12 million - $18 million. Omnicell expects full-year 2023 revenues to be between $1.135 billion and $1.155 billion, with non-GAAP earnings per share between $1.65 and $1.80.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.26%
Tags
-
Rhea-AI Summary
Omnicell, Inc. will release its financial results for the third quarter of 2023 on November 2nd. A conference call and webcast will be held to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
Rhea-AI Summary
Omnicell, Inc. to present at 2023 Wells Fargo Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
conferences
Omnicell, Inc.

Nasdaq:OMCL

OMCL Rankings

OMCL Stock Data

1.25B
45.23M
1.47%
101.18%
5.06%
Electronic Computer Manufacturing
Manufacturing
Link
US
Mountain View

About OMCL

since 1992, omnicell has been creating new efficiencies to improve patient care, anywhere it is delivered. omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. omnicell’s automated hardware/software systems for medication dispensing include solutions from the point of entry into the hospital through the central pharmacy, nursing unit, operating room, and patient bedside. our supply management systems promote greater cost control and charge capture for payer reimbursement, and improve management and reordering of inventory. omnicell® products range from high-security, closed-cabinet systems and software to open-shelf and combination systems in the nursing unit, cath lab, and operating room. more than 3,200 customers worldwide have utilized omnice